DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Meropenem Plasma Concentration Measurements at the Pediatric Medical Ward, Oslo University Hospital, Rikshospitalet

Information source: Oslo University Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Bacterial Infection

Phase: N/A

Status: Completed

Sponsored by: Oslo University Hospital

Official(s) and/or principal investigator(s):
Odd Brørs, Dr Med, Study Director, Affiliation: Oslo University Hospital
Margrete L Burns, BMed, Study Chair, Affiliation: Oslo univeristy hospital
Øystein Riise, PhD, Study Chair, Affiliation: Oslo University Hospital
Tore Abrahamsen, Dr Med, Study Chair, Affiliation: Oslo univeristy hospital
Gaut Gadeholt, Dr Med, Study Chair, Affiliation: Oslo University Hospital

Summary

The object of the study is to investigate whether all included patients receive treatment that is effective against all bacteria that are defined as sensitive to meropenem with the current treatment regimen. Will the investigators findings motivate routine monitoring of plasma concentrations in children receiving meropenem? Up to 50 patients will be included in the study, and all participants are children.

Clinical Details

Official title: Meropenem Plasma Concentration Measurements at the Pediatric Medical Ward, Oslo University Hospital, Rikshospitalet

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: We will determine how many of the patients in our material that have plasma concentrations of meropenem above 8 mg/l for at least 40% and 75% of the time.

Eligibility

Minimum age: 3 Months. Maximum age: 18 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Children aged from 3 months to 18 years that receive treatment with meropenem.

Inclusion is independent of how long the patient has been receiving treatment. Children receiving other treatment (except hemodialysis)/other medications can be included. Exclusion Criteria:

- Children less than three months of age. Patients receiving hemodialysis. Lack of

consent.

Locations and Contacts

Oslo univeristy hospital, Rikshospitalet, Oslo 0424, Norway
Additional Information

Related publications:

Ikeda K, Ikawa K, Morikawa N, Miki M, Nishimura S, Kobayashi M. High-performance liquid chromatography with ultraviolet detection for real-time therapeutic drug monitoring of meropenem in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Sep 1;856(1-2):371-5. Epub 2007 Jun 6.

Starting date: January 2011
Last updated: November 5, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017